Trial Profile
A Single Arm Exploratory Study of Chemotherapy Plus Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Locally Advanced Esophageal Squamous Cell Carcinomas
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- 07 Jan 2019 Status changed from not yet recruiting to recruiting.
- 20 Sep 2018 New trial record